I'm not sure Ecsc, but I suggest you take a look at Merck's...

I'm not sure Ecsc, but I suggest you take a look at Merck's pipeline:

http://www.merck.com/research/pipeline/home.html

You can see that are certainly comfortable to stack their pipeline with multiple candidates for the same disease (obviously boom areas dominate), so with only a single Phase I candidate for the common cold, I suggest Vapendavir would look very nice at the other end of the list (Phase III ready) and throw in Lani at Phase III ready and Biota suddenly looks like a cheap acquisition at 4-5 times current multiple - that is the factor Merck paid to get Idenix holders easily over the line - they jumped from around $5.50 to approx $23.50.

Plumb has form at least in selling Inhibitex (forget the fact that their lead candidate was a flop).

Let's monitor proceedings...